Omeros (OMER) Capital Leases (2017 - 2018)
Omeros (OMER) posted Capital Leases of $1.6 million for Q4 2018, up 94.81% sequentially from $810000.0 in Q4 2017, and up 94.81% YoY from $810000.0 in Q4 2017.
Powered by 
Analysis
Omeros (OMER) Capital Leases (2017 - 2018) Analysis & Trends
Omeros has reported Capital Leases for 2 years, with the latest figure at $1.6 million in Q4 2018.
- Quarterly Capital Leases rose 94.81% year-over-year to $1.6 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.6 million (up 94.81% YoY) and the FY2018 annual result came in at $1.6 million, up 94.81% from the prior year.
- Capital Leases advanced to $1.6 million in Q4 2018 per OMER's latest filing, from $810000.0 in the prior quarter.
- Over five years, Capital Leases peaked at $1.6 million in Q4 2018 and troughed at $810000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn |